Contents

Imagem2.png

Miguel Santos email

Short CV
Miguel Santos holds a BSc and a MSc degree in Biochemistry from Old Dominion University, VA, USA; a PhD in Molecular Biology from ITQB NOVA, PT; a Post-Doctorate in Genomics, UA, PT; a proficiency degree in Project Management (PMI Intl.), UAL, PT; a Mini-MBA in Global Biopharma Entrepreneurship, Rutgers University, NJ, USA; and a MBA from the Institute of Business Management (IBM) Lisbon. Miguel has occupied several managing positions within academy and industry. Recently, as COO at ECBio S.A., Miguel coordinated several aspects of Advanced Therapy Medicinal Product (ATMP) development and was responsible for the implementation and maintenance of the Research, Development and Innovation Management System according to the NP 4457:2007 (Intl. standard based on the Oslo Manual, Eurostat/OCDE, 2005). Miguel is currently an Affiliated Researcher at the Animal Science Studies Centre (CECA/ICETA - UPorto) and iMED (FF.ULisboa), and an Invited Principal Investigator at ITQB NOVA, where he coordinates the StartUp Research Program, in collaboration with the Venture Lab from NOVA SBE. Miguel provides consultancy in Open Innovation and New Product Development to Biotech StartUps and is presently a member of the Advanced Therapies Evaluation Committee, at INFARMED; and an Executive Board Member of the Portuguese Society for Stem Cell and Stem Cell-Based Therapies.

Topics
During the first day at the StartUp Research Program, we shall define Innovation according to the OECD Oslo Manual, Eurostat/OCDE, 2005, and analyse the advantages of an Open Innovation model and a Front-End view over other more conservative models of value creation. We shall analyse how we can apply the Open and Front-End Innovation processes to scientific research and learn how to separate the Innovation concept from Invention and Discovery. We shall then take a general view into the rainbow classification of the several faces of Biotechnology. Finally, we shall exercise the very first step of the Innovation Process Ideation. Creativity sparkles Innovation and you can create conditions to stimulate creativity by whirling around several well-established strategies, such as programmed brainstorming sessions or pre-scheduled retreats. However, Ideation is triggered when it is least expected, often during atypical circumstances.

Show less

starup_0001_Miguel_Pinto.jpg

Miguel Pinto email

Short CV

Miguel Pinto has graduated in Economics from the Instituto Superior de Economia e Gestão (ISEG), ULisboa. Presently, Miguel is a Partner- Advisory Services at Ernst & Young, Brazil, and has over fifteen years of professional experience. With a background in consultancy and in the front line of different industries, Miguel has been an important player within the organizations he has worked for, where he embraced a broad range of projects from setting high-level strategic direction and conducting enterprise-wide re-organizations to re-designing core processes. Before joining EY, Miguel was Managing Director for Strategos’ offices in Brazil and Portugal. Miguel took part in projects identifying new business strategies and building Innovation capabilities in several different industries - Telco, Media Entertainment, retail, football, construction and aeronautics, etc. - by developing a systematic approach to Innovation or identifying new growth platforms and new business models for his clients. Miguel is an Invited Professor within the Advanced Program in Entrepreneurship and Innovation Management at Universidade Católica, Lisbon, Portugal.

Topics
In a very demanding competitive landscape characterized by a VUCA (Volatile Uncertain Complex and Ambiguous) environment, companies and professionals must develop strong capabilities to innovate continuously. Agenda for discussion: 1. The Innovation Imperative – Why?, 2. The Innovation Myths - Lessons learnt about Innovation as a competence, 3 - Key principles for Innovation, 4 - Q&A.

Show less

starup_0003_ligia_gata.jpg Lígia Gata email

Short CV

Lígia holds a PhD in Agronomic and Environmental Chemistry, a MSc in Molecular Biology and Genetics and a degree in Veterinary Sciences. Lígia was a researcher for approximately 10 years but decided to dedicate her career to Intellectual Property since 1999, first as a Patent Examiner and PT delegate in several international IP forums, such as in WIPO, EU, EPO and WTO, and then as Director of the Patent Department in a IP-multinational company and later as Patent Counsel in a German biotech company. More recently, Ligia has been working as IP & Innovation Manager at Megaingenium, her own IP-based company.

Lígia is an European Patent Attorney (PQ), PT National Representative and Representative within EUIPO and WIPO.

Topics
Lígia will give a general talk about IP issues, focusing on a European perspective. Her talk will be sub-divided into the following sub-titles:
1. Introduction
2. Main IPR modalities
3. Protecting IP
4. Managing IP
5. Conclusions


Show less

starup_0010_Dipanjan_Nag.jpg Dipanjan Nag email

Short CV

Dr. Dipanjan “DJ” Nag led The Ohio State University’s startup, entrepreneurial ecosystem and licensing initiatives as the Associate Vice President of Technology Transfer. As the head of Technology Commercialization Office (TCO) his team managed 78 active startups. The TCO under his leadership more than tripled the revenues in two years and increased the inventions by 60% from nearly $1B in research expenditure.

As an entrepreneur he led a number of startups in the intellectual property strategy, artificial intelligence and medical device space. He has successfully assisted capital raise for many startup companies. As a successful consultant in patent monetization and intellectual property strategy he has worked with Fortune 500 companies, universities and national governments. From 2009-2012 he was the Executive Director, Office of Technology Commercialization, at Rutgers University where he successfully led the overall commercialization efforts, placing Rutgers in top 10 rank for start-ups. DJ was a Vice President at ICAP Ocean Tomo, a subsidiary of ICAP Plc, a $2B+ publicly traded company. Prior to that as a Director at Ocean Tomo, he led patent auctions, IP markets, and was an inventor of the first IP exchange (IPXI).

He served on the Board of Association of University Technology Managers (AUTM) responsible for professional development globally (2012-2014). He currently leads global education as the Sr. Vice President at the Licensing Executive Society’s (LES). In 2005, he received the prestigious Howard Bremer Scholarship in technology transfer. He is currently a Professor of Practice at Rutgers University, Lecturer at The Ohio State University and Visiting Faculty at Shizuoka University, Hamamatsu. He is an internationally acclaimed speaker and has delivered keynote addresses in USA, Japan, Poland, Brazil, Korea, Turkey and many other countries on topics of technology commercialization, intellectual property and innovation strategy. He holds a Ph.D. in biophysical chemistry and instrumentation, a MS in chemistry and computer sciences, a MBA all from UNL, and a Bachelors in pharmaceutical engineering from India.

Show less

startup__0001_Margarida Menezes.jpg

Margarida Menezes Ferreira email

Short CV
Margarida Menezes Ferreira graduated in Biology at the Faculty of Sciences of the University of Lisbon and she was awarded with a PhD degree in Medical Biochemistry at the Aix-Marseille II University in France, 1981. Margarida complemented her academic formation with post-graduate research in molecular endocrinology at the National Institutes of Health USA until 1984. She published several research papers in peer-reviewed journals, two of them selected for the Year Book of Endocrinology.

Margarida works at INFARMED since January 1996, the Portuguese Regulatory Authority for Medicines and Health Products having developed and supervised the installation of the Biologics, Biotechnology and Microbiology Departments for the National Laboratory for the Control of Medicines and Health Products, having coordinated its implementation until 2001. From 1999 to 2001 Margarida also directed the National Control Laboratory for Medicines and Heath Products (OMCL).

Since 1999, Margaria is the appointed member for the Biologics Working Party at the European Medicines Agency (EMA). She has participated in the drafting of European guidance and scientific advice on biological medicinal products including biotechnological and biosimilars as well as gene and cell based therapies. Margarida was member of the Cell Products Working Party until its closure and participated intensely in the construction of the regulatory framework and quality guidance for cell based medicinal products. Presently, and since its establishment in 2009, Margarida is the Portuguese representative at the Committee for Advanced Therapies (CAT), EMA.

Topics
available soon

Show less

starup_female.jpg

Mariana Madureira email

Short CV
available soon

Topics
available soon

Show less

starup_female.jpg

Isabel Borba Vieira email

Short CV
available soon

Topics
available soon

Show less

tutor-CarolinaSantos.jpg

Carolina Santos email

Short CV
Carolina Isabel Rêgo Récio Santos is Project Management certified by the Internacional Project Management Association (IPMA) and the Portuguese Association of Project Management (APOGEP). She teaches project management at NOVA-ENSP and NOVA-Doctoral School. 
She holds a PhD in Public Health, specialization in Policy, Management and Health Administration (2019) from ENSP-NOVA; and a MSc in Health Management (2010) from ENSP-NOVA. 
Her PhD output was a model of success factors for public health projects and her fields of expertise and publication are success in project and programme management.  
From 2014 is part of the organizing and scientific committees of ProjMAN - International Conference on Project Management. 
She integrated several research teams at NOVA-ENSP between october 2009 and december 2013 and co-authored publications in health economics and road safety matters.

Topics

- Basics in project management (e.g.: project, operation and project management) 

- PM standards 

- Project success criteria and factors 

- Projects, programmes and portfolio

- Project lifecycle 

- Project core areas: Scope,  Time, Organization, Stakeholders, Resources, Quality, Communications, Costs, Risks

- Integration tools: project charter, project plan

- Individual competence baseline for project management​: behavioural and contextual skills.

Show less

statrup_0000_TomasBaena.jpg

Tomás Baêna email

Short CV
Clinical Psychologist, MA in Philosophy and MSc in Communication, Behaviour and Credibility Analysis by Manchester Metropolitan University, Emotional Intelligence Academy and Paul Ekman International. Director of the International Institute of Body Language (InBodyLanguage) and Researcher at Centro de Investigação de Direito Penal e Ciências Criminais da Faculdade de Direito da Universidade de Lisboa. Vice-President of the Scientific and Educational Board of International School of Professional Coaching, Credentialed Coach by International Coach Federation and NLP Trainer at Instituto Internacional de Programação Neurolinguística. Professional Trainer with more than 8,000 hours of work experience and Guest Lecturer at Faculdade de Medicina da Universidade de Lisboa, Universidade Fernando Pessoa and Institute of Business Management.

Topic I - Body Language Workshop
This workshop will start with the examination of the biological and phylogenetic basis for facial expressions and body movements, as well as the leading research concerning nonverbal language, emotions and behaviour. There will be three main pillars in this presentation. Firstly, the description of scientific methods for the identification of basic emotions in others through the analysis of specific facial muscles. The chief heuristics that prevent this analysis will also be underlined. Secondly, the positive and negative effects of the entrepreneur’s own body language on others’ perception will be examined. The main cultural and biological biases of people’s perception concerning body language will likewise be surveyed. Thirdly, the influence of the entrepreneur’s own body postures on his/her behaviour will be analysed, as well as practical strategies to enhance emotional states.

Topic II - Coaching & Self-Assessment Workshop
This workshop will present a historical overview of the concept of Coaching, as well as its primary models and applications. Four main elements will be underlined. Firstly, the use of Coaching as a self-assessment communication tool for entrepreneurs to plan, develop and sustain professional goals will be examined. Secondly, the chief neurological, behavioural and linguistic features that prevent and facilitative effective goal achievement will be described. Thirdly, the role of motivation and emotional intelligence in behaviour change will be analysed. Finally, there will be a presentation of several strategies and practical tools for the development of a clear, flexible and cooperative communication in professional contexts.

Show less

starup_0005_Isabel_Motta_Mendes.jpg

Isabel Mendes email

Short CV
Graduated in Public Relations and Advertising at Instituto de Novas Profissões of Lisbon, works as Copywriter since 1995. As a Copywriter trainee, was in Curitiba, Brazil, in one of the biggest agencies of the state of Paraná. Back in Portugal, worked in national agencies where developed writing skills in several communication’s disciplines, from advertising to promotional and behavioural marketing, graphic design, branding and even political marketing. In 2010, co-founded the Frank & Stein brand (closed in 2017) where she has developed all the copywriting work and shared the creative direction. Currently, Isabel works as a Freelance Copywriter for several agencies and companies and teaches Copywriting at Escola Superior de Gestão – Instituto Politécnico de Santarém (Marketing and Advertising course).

Some brands in Isabel’s portfolio: Galp Energia, Mercedes-Benz, Hyundai, CTT, Sical, Robbialac, ANA Aeroportos, L’Oréal Professionnel, Danone, Caves Aliança, Lojas Singer/Excel, Oney Bank, Fidelidade, among many others.

Topics
How can communication contribute to engage the non-scientific community with a scientific project:

1. Less is More: Communication Concepts.

The importance of summarizing a project in a couple of lines. Yes, that’s right: just a couple of lines. After all, a simple idea is easy to understand by everyone.

2. You Talkin’ To Me? Target Audiences.

How identifying the specific receivers of the message is crucial to communicate with efficiency. And how more than one target audience may require adjustments to the same message.

3. My project is your project: Message.

The time has come for a project to leave the nest. From now on it will be shared with specific audiences. What do they (each of them) want to hear? What do they value? Seduction is a game of words and the better they are used, the better are the results.

Show less

tutor-AnaLeal.jpg

Ana Leal email

Short CV
Area Manager and Senior Project Manager at the International Unit at INOVA+ (http://inova.business), which specialises in initiatives of international dimension, usually implemented with external funding. Before joining INOVA+, she collaborated as a consultant and project manager with various organisations. For more than 12 years, she is being coordinating and participating in international funded projects in different fields, contributing to build communities and boosting cooperation across countries and sectors. In parallel, she has experience in procedures related to the technical, financial and administrative aspects required for the preparation and submission of applications to EU funding programmes, including H2020. In this area, she supports several type of organisations in the elaboration of proposals, ensuring the alignment with programme requisites. She holds a degree in Human Resources from the College of Industrial Studies and Management, Polytechnic Institute of Porto and a Specialization Course in Human Resources Management and Development from the same Institute.

Topics
available soon

Show less

startup_bernardo_pimentel.jpg

Bernardo Pimentel email

Short CV
Bernardo Melo Pimentel is an Assistant professor at NOVA SBE. Bernardo holds a Ph.D. in Management (Entrepreneurship) from NOVA SBE with BSc and MSc degrees from the same institution.

Bernardo's main research interests lie in the application of econometric methods to the study of entrepreneurial careers, decisions, and outcomes. This line of research evolved towards the understanding of the role of entrepreneurial ability in the market for firm acquisitions. In another project, Bernardo analyzed determinants of MNC divesture and knowledge spillovers to local employment and firm creation.

At present, Bernardo teaches Principles of Management for the undergraduate Management and Economics degrees. Additionally, he collaborates with ISEG Lisbon where he lectures for the Economics, Finance, and Management programs and with Audencia Business School where he serves as an external professor for the M&A and Strategic Alliances masters course. Previously, he was a research fellow at Instituto Superior Técnico.

Topics I

a) Introduction to Management

b) Business strategy & strategic thinking

c) Creating and managing a business

d) Business planning vs Entrepreneurship

Topics II

a) Industry analysis (e.g., Porter, SWOT, PESTAL)

b) Customer and market research

c) Opportunity mapping and Insights;

Show less

startup_fabio_santos.jpg

Fábio Santos email

Short CV
Fábio Santos is an Assistant Professor (Adjunct) at NOVA SBE. He currently teaches Finance in the Undergraduate program. In the past Fábio conducted theoretical classes in Finance, Statistics, and Problem Solving. He has also been a teaching assistant for Calculus, Accounting, Macroeconomics Principles (among others).

Fábio has a Master’s degree in Finance from NOVA SBE and an Undergraduate degree from the same University.

Besides the academic experience, Fábio holds a business career at Sonae after his consulting experience at AT Kearney and in NOVA SBE projects.

Topics

  1. Key partners, Activities and Resources
  2. Corporate finance: the balance sheet, the financial view of the firm – assets and liabilities,
  3. Financial analysis – how to calculate the main financial indicators – TIR and VAL and do analytical analysis of a R&D / Entrepreneurial project.

Show less

Nuno Arantes Oliveira_Photo.jpeg

Nuno Abrantes Oliveira

Short CV

Nuno Arantes‐Oliveira is an entrepreneur, investor and academic with a scientific background and an interest in innovation, particularly in the Life Sciences and in Healthcare. Nuno is Partner and Chairman of Clinical Research Ventures (CRV), a Singapore-based global investment fund focused on clinical-stage biotech and medtech companies. He is also Chairman of the Investment Committee of 200M, a State-backed co-investment fund based in Lisbon; Chairman of Oceano Fresco S.A., a pioneer bivalve aquaculture company; and a shareholder and advisor of several life-science companies in Europe and the United States. Nuno also owns a pediatric specialties clinic in Lisbon and is an advisor to the rectory of NOVA University. Nuno began his career as an invited graduate student working on the genetics of aging at the University of California San Francisco (UCSF). There his research led to the largest lifespan extension ever observed in any living being (more than 6‐fold), which in turn originated a string of high-impact papers, including three in the journal Science. Later Nuno did a post-doc on Innovation and Entrepreneurship in Biotechnology, and at the same time became the first Managing Director of a pioneer technology-transfer company working with Portuguese R&D organizations. In 2005 Nuno became a founder and the CEO of Alfama, one of the first drug development companies to originate from Portugal, which was then voted the Best Start-up in Europe. Alfama, Inc. was incorporated in the United States (Cambridge, MA) and through growth and acquisitions became the dominant player in the field of carbon monoxide (CO)-based therapies, before being itself acquired by Proterris, Inc., of Boston. Nuno also founded Coimbra Genomics S.A. (voted a top‐3 promise in European e-Health, 2015) and helped launch the Innovation and Translational Research Units of IPATIMUP, a leading cancer research institute (now part of I3S). In the meantime, Nuno served as President of P‐BIO – Portugal’s Biotechnology Industry Organization from 2011 to 2015 and sat on the board of Health Cluster Portugal from 2008 to 2013. Nuno has had multiple other board, advisory and expert roles internationally, including with Government authorities and top‐tier research organizations, and has negotiated and implemented business and scientific collaborations in Europe, the U.S., China, Africa and Latin America. He also took executive courses at the Harvard Business School and other prominent schools. Keeping one foot in academia, Nuno was an invited assistant professor of the MIT‐Portugal Program (2015-18) and is now an invited associate professor at NOVA School of Business and Economics (NOVA-SBE), where he teaches Science-based entrepreneurship.

Nuno is based in Paço de Arcos, near Lisbon, where he lives with his wife Sofia and their three children.

 

Topics

  • What is Innovation?
  • Types of Innovation
  • The Importance of Entrepreneurship
  • Success and Failure
  • The Role of Storytelling
  • My Own Path – assorted stories on: Aging Research; Tech Transfer; Drug Development; Digital Health; Healthcare Services; Aquaculture; Teaching Innovation; Venture Capital.
startup_anibal_lopez.jpg

Anibal López email

Short CV
Aníbal is a teaching assistant of Entrepreneurship at NOVA SBE. Aníbal holds a PhD in Management (Entrepreneurship) from NOVA SBE. Aníbal previously worked as researcher assistant in different research projects in organizational behavior field. His main research interests focus obstacles to entrepreneurship, entrepreneurial passion and new venture management. Aníbal is currently responsible for the academic programs of the NOVA SBE’s Innovation and Entrepreneurship knowledge center (Venture Lab).

Topics I

a) Customer segmentation

b) Customer Development Process

c) Design Thinking

d) The scientific method applied to Customer Validation

Topics II

a) Traditional approach vs Entrepreneurial approach

b) Sales and business development

c) Growth Hacking

Show less

startup_Teresa.jpg

Teresa Mannebach email

Short CV
Teresa Moana Mannebach is a Mentor and Advisor in the knowledge center for Innovation and Entrepreneurship (Venture Lab) at NOVA SBE. Since 2014, Teresa is a teaching assistant for courses related to Innovation and Entrepreneurship, Family Business and Strategy Consulting. Teresa adds on to her academic knowledge with experience from being a business developer at wonkyboard.com and an entrepreneur - she launched her own business in 2014 (Slide Surfcamp). She holds a Bachelor of Science in International Business from Maastricht University and a Master in Management with specialization in Innovation and Entrepreneurship from NOVA SBE. Teresa's areas of interest include besides Innovation and Entrepreneurship, Sustainability, Ocean Health and Surfing.

Topics

a) Business Model Generation

b) The value proposition Canvas,

c) The Business Model Canvas

Show less

John Freshley_Photo.png

John Freshley

Short CV

Based in Ann Arbor, Michigan, John Freshley is a high-energy entrepreneur, company builder and leader with 20+ years experience in a wide variety of healthcare-focused companies launching and operating in a region outside of the biotech “hubs” – not unlike Portugal. He has founded, launched, and/or led 8 early stage life science companies resulting in successes, failures, and always lessons learned.

Most recently, from 2013 through April 2019, Freshley served as President & CEO of ONL Therapeutics, an emerging ophthalmology company focused on preventing the death of retinal cells. During his leadership, ONL raised $11M+ in equity and non-dilutive funding, while advancing its lead candidate from discovery to clinical development with the Phase-I trial starting in October 2019.

Mr. Freshley is 50% Portuguese by heritage, which fuels his interest in helping build the entrepreneurial ecosystem in Portugal, and is learning.

 

AlexandraVeiga_web.jpg

Alexandra Veiga email

Short CV
Alexandra Veiga is a Research Manager at Nova SBE. After her post-doctoral studies and over ten years of research activity, Alexandra worked for four years as Senior Officer at the Portuguese Food Safety Authority where she was also member of the Scientific Committee. She was then invited to set up the Research Management Office at ITQB – NOVA, a research institute in the Lisbon area. Five years later she moved to the National Funding Agency (FCT) to create a new position of Senior Officer for Nuclear Affairs along with an activity as National Contact Point (NCP) for Horizon 2020. Her diversified work experience gave her a comprehensive perspective of the research field. As an academic, she published eight papers. While working on Food Safety, she published two book chapters, was member of Editorial Boards, evaluated research proposals for the EC and other funding entities, participated in the decision process to launch calls to fund research, and did consulting in Africa. As research manager, she gained a deep knowledge on funding agencies’ policies, contributed to the definition of institutional funding strategies, and trained and assisted researchers in the preparation of grant applications. Alexandra has also a thorough knowledge of European institutions: she was member of the H2020 Programme Committees; was appointed as member of the Governing Board of the Fusion for Energy; was the country representative in several meetings to the European Food Safety Authority; and participated in several working groups that supported European institutions activity. Moreover, Alexandra is experienced in other international fora: she was the Portuguese representative in the UN International Atomic Energy Agency, and participated in NATO pilot studies.

Show less

starup_0008_Helder Cruz.jpg

Helder Cruz email

Short CV

Helder Cruz has a 5- year degree in Applied Chemistry (branch of Biotechnology) from FCT-UNL, an MBA in International Businesses from Universidade Católica Portuguesa and a PhD in Biochemical Engineering from ITQB-UNL. After getting the PhD degree, the applicant had several activities (some in parallel):

- Post-doc at the GLP Lab at IBET in the development of cell-based assays;

- Senior researcher started at Biosensors Lab from ITQB-UNL; has authored several publications as well as co-supervised master and PhD students;

- Consultant for biopharmaceutical companies (US, EU and PT). He was member of a Board of Directors and of Scientific Advisory Boards;

- Invited professor of Bioengineering for a MSc Program (ESSCVP, Lisbon) and of Biochemistry, Enzymology, Molecular and Cellular Biology (UnI, Lisbon);

- Co-founder & CEO of ECBio S.A.;

- Currently evaluator and reviewer of research projects financed by the European Commission;

- Currently Co-founder & CEO of Theraproteins Lda. and BioPharma Consultant.

Show less

SusanaFilipe_web.jpg

Susana Filipe email

Short CV
Susana Filipe has 18 years professional experience in Biotech and Biopharma start-ups and companies, namely within the Oncology therapeutic area. Currently, as Project Manager – Biopharmaceuticals at Pharmis Biofarmacêutica, she has the responsibility for the creation and development of a new business unit – biological medicines, design and management of R&D projects, including funding opportunities; is responsible for finding and establish collaborations with the appropriate institutional partners and gives support to the management team regarding product and clinical development. Occasionally she is also involved in the elaboration of Business/Marketing plans for the launch of new pharmaceutical products. Academically she holds a Ph. D. in Biochemistry and a Master in Pharmaceutical Industry and has taken courses in Project Management and Medical Marketing/Medical Affairs.

Show less

Ana Cadete.jpg

Ana Cadete email

Short CV
Ana takes the role as a Formulation Scientist in the Delivery Sciences Group at Moderna, a biotech company focused in the development of mRNA therapies to create a new generation of medicines for patients. Ana is responsible for the design and formulation of nano-carriers to delivery mRNA in the body. Previously, Ana was a postdoctoral researcher in the Langer Lab (Koch Institute, MIT) in collaboration with Novobiotic Pharmaceuticals, working in a project funded by Bill and Melinda Gates Foundation to target tuberculosis. During this year, Ana developed an interest in the innovation and entrepreneurship side of science. She took the MIT i-teams course, a “think out of the box” program leaded by Luis Perez Breva, and the BiomedStartup, a two-week program focused in taking further biomedical research that impact patient’s life. Ana’s doctoral work was a joint doctorate Erasmus Mundus Program – NANOFAR – at University of Santiago de Compostela, Spain, and University of Angers, France. During her PhD studies, she was an intern at Bind Therapeutics, in Cambridge, MA. Before, she worked in the R&D department of Sylentis, an siRNA company based in Madrid, Spain. She is also the executive director of the International Mentor Program, where she leads a team of Portuguese mentors working abroad and connect them with Portuguese students. She believes mentoring is a powerful tool to give value back to her country.

Show less

startup_miguel_munoz.jpg

Miguel Muñoz email

Short CV
Miguel is the Executive Director of NOVA SBE Venture Lab - Nova SBE Entrepreneur and Innovation Center, established in 2017. Since 2014, Miguel works as an Assistant Professor at Nova School of Business and Economics (teaches entrepreneurship to undergraduate and master's degrees). Miguel is an entrepreneur with several businesses launched (until 2008 a Strategic Marketing Agency and since 2008 an Innovation and Creativity Consultancy). Since 2014, Miguel is also an Invited Mentor, Lecturer and Speaker for several incubators and acceleration programs. From 1999 to 2004 he was the Marketing Manager and Senior Marketeer at DANONE PORTUGAL / DANONE MEXICO, and from 1997 to 1999 he was a Marketeer at HENKEL IBÉRICA. Miguel holds an Economic Degree from NOVA SBE and Master in Entrepreneurship and Innovation from ISCTE-IUL.

Topics I

  1. The several stages of business development: 1-Go /No-Go decision, 2- Types of corporations, 3-Types of starting funds & investments, 4- Initial structure and organization of a successful Spin Off / Start Up company, 5- Common mistakes and hints to success – case studies.
  2. How to lead your venture in different stages of development.

Topics II

  1. How to prepare a pitch
  2. Funding options

Show less

starup_0011_cristina_spereira.jpg Cristina Silva Pereira email

Short CV

Cristina Silva Pereira is an Associate Professor at ITQB NOVA (since 2017), where she leads her research group (since 2008). Cristina is also an Invited Researcher at the University of the West of Scotland (UK). Cristina's research focus has always been problem-driven, often leading her to cross-perceive discipline boundaries, such as those of Chemistry and Microbiology. Cristina studied Applied Chemistry - Biotechnology (FCT NOVA) and started her research career at iBET. During her PhD, Cristina worked at ITQB NOVA, the John Innes Centre and the Institute of Food Research (UK). After the conclusion of her doctorate (2004), Cristina worked as a postdoctoral fellow in Microbiotechnology (3 years) and in Green Chemistry (1 year), both involving liaison and travelling between national and foreign institution. In 2007, Cristina was awarded an EEA research grant of nearly €1.5M, a competitive Starting Research Ciência 2007 contract and the national Professor António Xavier memorial award for young scientists. In 2008, Cristina established her research group. In 2015, she was awarded a Consolidator Grant by the European Research Council (ERC), to develop her vision of mimicking the functionality of plant polyesters to develop wound dressing biomaterials that combine antimicrobial and skin regeneration properties. She is also a partner in a FET Project which seeks inspiration from natural aqua-melts to develop new bioplastics. Cristina is the mother of a 6-year old boy.

Topics
Cristina will focus on her research path as the case-study to emphasise the tactics she has used for defining strategic scientific fields which would potentially led to Innovation, hence funding by both private and governmental sources. Cristina will revise concepts she has learnt through experience and short training sessions in management and communication. Cristina will expose the “dos and don’ts” sharing the reasons to have won or to have failed some important negotiations (e.g. NATO sfp, Merck, Amorins, ERC). Cristina's vision is the scope of the StartUp Research Program is to share her enthusiasm for science and for Innovation and to communicate her research philosophy.

Show less

starup_0004_isabel_rocha.jpg

Isabel Rocha email

Short CV
Isabel Rocha is Pro-rector for Innovation and Entrepreneurship at NOVA University. During 2007 Isabel was a visiting scholar at the Massachusetts Institute of Technology, USA, as part of the MIT-Portugal Program, where she attended several courses in Innovation and entrepreneurship at the Sloan School of Management. She is part of the MIT-Portugal faculty and was, from 2007 to 2017, in charge of a Portuguese educational program in Innovation involving 4 universities and 2 PhD programs – the i-teams program. Isabel was the President of P-Bio, the Portuguese Bio-industries Association and she is also one of the founders and scientific coordinator of two companies that won several national prizes in entrepreneurship, being involved in major industrial biotechnology projects worldwide – SilicoLife and Biotempo.

Isabel does her research at ITQB NOVA and Minho University in Biotechnology covering the topics of Metabolic Engineering and Systems Biology and has published over 120 full papers in international journals, books and international conferences. She is the Principal Investigator of several projects being involved in collaboration projects with research institutions worldwide. Isabel is the national representative in the European Infrastructure for Bioinformatics, the ELIXIR.

Topics
In her session, Isabel will cover the topics of Innovation in biotech using genetic modifications, focusing mostly in industrial biotechnology (bioprocess engineering) but also broadly covering other areas such as agricultural innovations.

Isabel will discuss future trends, regulatory limitations and intellectual property applied to those areas. Isabel will also share the example of SilicoLife, a company that designs computationally microbial strains for producing a variety of bulk and specialty compounds, by performing gene deletions, gene over/under-expressions and the insertion of heterologous genes, for example from plants into microbes.

Show less

starup_0002_ligia_martins_CSP2554.jpg

Lígia O Martins email

Short CV
Lígia O Martins is leading a research group at ITQB NOVA focused on enzyme discovery, engineering and application in the conversion of natural and synthetic aromatics. Lígia is/was Principal Investigator in 9 research projects, 2 of which funded by the European Commission, and national delegate of two COST actions. Lígia is part of the Scientific Committee of the PhD Program in Sustainable Chemistry jointly hosted by Aveiro, Porto and NOVA Universities and of the Master Course in Biotechnology for Sustainability (ITQB NOVA) where she holds the chair of Environmental and Industrial Microbiology and Biocatalysis. Lígia has 68 papers in high impact journals (12 with 100+ citations, three journal covers) and she has been involved in the supervision of 6 Post-docs, 9 PhD and 10 MSc students. Lígia is member of the Scientific Committee of the Bio-based Industries Joint Undertaking (2014-20).

Topics
Plant biomass has emerged in recent years as an extremely attractive renewable source of chemicals, materials and fuels. It is widely believed that their mere abundance can facilitate the switch to a bio-based economy and replace the petrol-based industry that we have been relied upon. However, the full development of sustainable bio-refineries is critically dependent on an efficient separation and conversion of biomass constituents (cellulose, hemicellulose and lignin) in the same way petrol refineries separate oil fractions to provide diverse fuels and chemicals. Biocatalysis offers an environmentally-friendly tool to disentangle recalcitrant biomass feed stocks, a top priority area in the EU and worldwide. In this lecture, Lígia will highlight the key role of research in industrial biotechnology in supporting the economic health of the bio-refinery vision that will lead to increasingly knowledge-based, sustainable and inclusive economy.

Show less

starup_0009_paula_alves.jpg

Paula Alves email

Short CV
Paula Alves is CEO of iBET and Head of the Animal Cell Technology Unit at iBET and at ITQB NOVA, and Invited Associate Professor of Chemical and Biochemical Engineering at the Faculty of Sciences and Technology, also at NOVA University. Paula Alves has extensive experience in understanding cell metabolism to improve the efficiency of bioprocesses and at developing new tools and technologies for pre-clinical research. More recently this expertise was expanded to generate expansion and differentiation of stem cells in bioreactors.

The Unit Paula coordinates uses Animal Cell Technology for research and development in particular for (i) production of complex biopharmaceuticals such as viral vectors, vaccines and recombinant proteins (ii) development of 3D culture systems for toxicity testing using primary cells and stem cells in bioreactors (iii) expand systems biology approaches to organize the complexity of the processes involved in the research described in (i) and (ii).

Paula is President of the ESACT-European Society for Animal Cell Technology and Member of the Advisory Group for Horizon 2020 Societal Challenge 1 and of the ESAC Expert Group (European Commission). Paula has published over 220 papers, 29 book chapters and supervised 26 PhD students and 10 Pos-docs.

Topics

Red biotech represents the largest impact of biotechnology given its contribution to human health and as the principal biotechnology driven business area. Paula Alves will present briefly iBET pathway to become a top European Research and Technology Organization with a global reputation on the Biologics arena.

The complementary activities of an iBET spin off – GenIBET - will be briefly presented highlighting how the investment in “science driven projects” allowed iBET to increase strength as a Contract Research and Development Organization while GenIBET supports the whole effort as the Contract Manufacturing Organization producing Biopharmaceuticals under cGMP for early phase I and phase II clinical trials.

As Monoclonal Antibodies (the Biologics Blockbusters) are now entering a mature phase Paula will mainly focus on the impact of Animal Cell Technology on development of the “new comers in the business” – ATMP´s (Advanced Therapy Medicinal Products). Case studies covering cell therapies (from stem cells to human cardiomyocytes) and gene therapies (oncolytic adenovirus in cancer treatment) will be presented.

Show less

starup_female.jpg

Manuela Pintado email

Short CV
available soon

Topics
available soon

Show less

startup_pedro_fevereiro_.jpg

Pedro Fevereiro email

Short CV
available soon

Topics
available soon

Show less

starup_0012_Sofia_Tahar.jpg

Sofia Ben Tahar email

Short CV

Sofia Ben Tahar has a PhD in Animal Molecular Biology from Paris VII and 2 Post-Docs on Plant Genetic Engineering at CSIRO Australia. For 5 years Sofia was Manager Director of Biocem, a Plant Biotechnology Laboratory of Limagrain based in France. She has worked on Licencing In and Out the outcome results and has published patents. Sofia has worked as an expert consultant in crop Biotechnology for FAO, for Ireland Science Foundation and as a legal expert. The worldwide use by the company of New Technologies in crop production brought Sofia to build different networks and to settle a Risk Quality Management System in different business units. The Management System covers the areas from research to commercial products at Global level for field crops, vegetables and food products. Sofia trains and communicates on Plant Biotechnology in different Schools and Universities. Sofia is Chairing the group working on the Methods of Detection using Molecular Biology at AFNOR. She is expert auditor at COFRAC for detection laboratories.

Topics
The potential of Crop biotechnology to improve agriculture has been demonstrated since more than 21 years. It has helped achieving agriculture sustainability and development. More than 60 countries from all over the world have either planted or imported biotech crops. Since 1996, 2 billion hectares were planted in more than 30 countries. The major growing Biotech crops are maize, cotton, soybean and canola. The market for seeds and technologies fees have increase since 1996 from 0.1 billion$ to 15.8 billion $ in 2016. These traits have increased crop productivity, helped conserved biodiversity, reduced agriculture eco-foot print and finally have contributed to the alleviation of poverty and hunger. Recently merger between very large companies and the new gene edited crops will increase the potential market of crop biotechnology with a strong effect on agriculture development

Show less

startup__0005_Carlos Malpica.jpg

Carlos Malpica email

Short CV
Carlos Malpica Lizarzaburu was trained in France as an Agronomic Engineer at Institut National Agronomique Paris-Grignon and Pasteur Institute and obtained his PhD in Biotechnology from Paris University 7. Additionally he holds a diploma from the Spanish Diplomatic School and an International Executive MBA from Instituto de Empresa (Spain).

Carlos is the CEO of MLP Vision Biotech S.L. and Valdia Health S.L. He is actively involved in promoting the adoption of new precision medicine tools based on multi-omics technologies. Carlos is also the Vice-President of BioEuroLatina, a non-for-profit organization that aims at fostering the collaboration between Europe and Latin America in Biotechnology.

Past activities include Global Business Development Director and European Director at Metabolon Inc. (USA). Marketing and Sales Director at Biopolis S.L. (Spain), Research Director at L’Oréal Group (France), CEO of Kina Biotech S.L. (Spain), Global Business Development Manager at Syngenta A.G. (Switzerland), Head of Business Development Europe at Novartis Seeds S.A.S. (France) and Biotechnology Research Coordinator at the DANONE Group (France).

Topics

Using the example of Valdia Health SL, Carlos will share his experience in managing innovative knowledge-based life science companies which offer services rather than products.

Valdia Health provides a multi-omics approach for convenient, state-of-the-art and actionable support to decision making in diagnostics.

The company processes samples and integrate omics data in a one-stop shop for the most advanced commercially-validated diagnostic decision-support tools including proprietary own-developed tools.
The company does not provide a diagnostic report but rather specific value-added clinically-relevant information, which will enable clinicians to produce an accurate diagnostic with potentially actionable therapeutics.

To veterinaries the company also offers ad-hoc services for their clinical needs with support from the most advanced research organizations in animal health.

Show less

startup__0000_Mike.jpg

Mike Jagielski email

Short CV
Mike Jagielski is the President and CEO of KCR, a contract research organization operating internationally, leading the organization for more than 5 years. Dr. Jagielski has over 20 years of experience in global clinical trial operations industry with focus on strategic leadership for full-service and large-scale operations projects.

Under Mike's leadership KCR has further developed to become an important market player in the CRO industry, successfully combining the company geographical coverage with strategic trial execution.

Mike is a thought leader defining the CRO industry trends and commenting on the business models to be adapted for successful cooperation with the pharma and biopharma industries.

Mike Jagielski is also playing a significant role in advocating for patient-centric approach in clinical studies. He is a seasoned presenter speaking at the main industry events e.g. Partnerships in Clinical Trials (PCT).

Prior to joining KCR Mike spent 13 years with Merck & Co., where he held various positions in Germany, Belgium, Finland and the U.S.

Topics
CROs are an integral part of the global pharma and biotech drug development process. CROs are providing vital research services historically focusing on the execution of Phase1 to Phase 4 clinical research projects. The business models are historically hourly based service models: different hourly rates for different level of service provision. This is very similar to other industries such as consultancy or business process outsourcing (BPO). The lecture will explain in detail the two main CRO business models and analyze advantages as well as disadvantages. In this lecture we will also review alternative business model options and judge possibility to adapt these considering the existing market forces. The controversy the CRO business model faces is that operational efficiencies would drive revenues down in an hourly business model. If CRO substantially improve efficiencies, it might lead to less financial success as CRO selection does not only depend on efficiencies. In the 90 minutes lecture we try to shine light to this controversy and will explain the basics elements of the CRO business model.

Show less

startup__0003_ORFEU FLORES.jpg

Orfeu Flores email

Short CV
Orfeu Flores has a degree in Applied Chemistry (1992) from NOVA University, Portugal, a MSc in Science and Technology Commercialization (1998) from IST-Texas University, USA; and a PhD in Molecular Genetics (2015) from ITQB NOVA.

Orfeu is founder and CEO of STAB VIDA (www.stabvida.com), a Portuguese ISO9001:2008 certified biotech SME established in 2001, currently with 30 employees and a dedicated line of products and services for genetics and genomics (http://www.stabvida.com/en/services/catalog). Its main R&D and commercialization interests are focused in point-of-care diagnostics and theragnostics (mainly for Alzheimer, Lyme and Cancer), oligo synthesis, bioinformatics and nucleic acid sequencing, including next-generation sequencing (NGS), for the biotechnology and biomedical research and clinical community.

Orfeu has a large experience in biotech entrepreneurship, having received several Entrepreneurship Awards by the Portuguese Association of Young Entrepreneurs, the Rotary Foundation and the Gulbenkian Foundation. Expert for European Commission RTD FP5, FP6, FP7 and H2020, member of several panels for project evaluation, since 1999; Project Technical Assistant for European Commission RTD FP6 in Genomics and diseases of genetic origin, since April 2000. Orfeu holds large experience in training and sequencing- methods (Sanger and NGS) as well as bioinformatics.

Topics

What is the difference between a Start-Up and a Spin-Off? Between a distributor and a company with its own catalogue?

Should the Portuguese biotech (and European in general) invest in services or products? And how the digital revolution interferes with this debate?

These and other questions will be approached for both, purely academic scientists and scientists with more entrepreneurial mindsets.

Show less

starup_0007_gilgoncalves.jpg

Gil Gonçalves email

Short CV
Gil Gonçalves is an Assistant Professor at the University of Porto and the Chief Scientific Officer of INOVA+. With an extensive experience in research, Gil has been involved in over 35 National and European RTD projects and has been the Principal Investigator in over 20.

Gil is also an experienced entrepreneur. Part of the team that won the Portuguese National Innovation prize (CNIBES) in 2006 with the project SeaScout, he was later involved in the project “Marine Systems and Technologies” financed by the Portuguese Innovation Agency for the creation of a high-tech spin-off based on research results. Since 2006 he was founder of 3 other high-tech based start-ups.

At the University of Porto, Gil is responsible for the course Project Management Laboratory that involves close to 250 students from different integrated masters (4th year) and masters programs. This course works a Living Lab for professional skills development that brings together industry and academia, helping students to develop project management skills and team work skills while implementing concrete software development projects.

Topics
The success of projects depends not only on the technical and scientific skills necessary to perform the various research and technical activities, but also on a set of soft and management skills, such as project management skills (in its various variables of time, budget, scope, quality, resources, etc.), leadership and teamwork, as well as communication and business skills. This workshop will look into the project management body of knowledge (PMBOK) and will address the following areas of knowledge: scope management, time management, cost management, quality management, human resources management, communication management, risk management. Different methodologies (structured, agile, etc.) will be discussed and several examples from previous and/or on-going research projects will be presented. Students will be invited to develop and present the project plan for their research project.

Show less

Rita Abranches_Photo.jpg

Rita Abranches email

Short CV

Rita Abranches is a Principal Investigator and the head of the Plant Cell Biology Laboratory at ITQB NOVA. Rita studied Agricultural Engineering at Instituto Superior de Agronomia, Universidade de Lisboa, and got a PhD degree in Biological Sciences at the John Innes Centre/University of East Anglia, UK, in 2000. From 2000 to 2002 she worked as a research associate at North Carolina State University, USA. In 2002 she returned to Portugal as a postdoctoral researcher at ITQB NOVA, and in 2004 she started her own research group at ITQB NOVA. The main objective of her current research is to integrate the fundamental and applied aspects of Molecular Farming - the production of recombinant proteins in plant based systems - by determining which processes influence recombinant protein expression, accumulation, and stability.

Topics

In this talk I will give an overview on the most recent trends and applications of Plant Biotechnology. Plants have been used since ancient times for medicinal purposes. Nowadays they are used as platforms for production of biopharmaceuticals, vaccines, cosmetics, natural dyes and many other high value compounds. Although the first plant made biopharmaceutical for human application reached the market in 2012, many challenges remain as the market for biopharmaceuticals is growing fast. In this session we will discuss how plant-based systems can be cost-effective alternatives to conventional production platforms, and the advantages they offer such as their enormous versatility. We will also travel through a number of biotech companies around the world which use plant cells and other photosynthetic systems for the production of valuable molecules.

justin mulde.jpg

Justin Mulder 

Short CV

Justin Mulder is an experienced starter who has a passion for Economics, Agriculture, and Politics. He holds Diplomas in Business Management as well as Economics. Justin has been passionately pursuing the advancement of the legal Cannabis industry for over 5 years and moved to Portugal in 2015 to obtain licenses from the Portuguese government to Cultivate, import, export & consult in all matters concerning cannabis sativa L (Hemp) and its derivatives. Justin is currently the Co-Founder & Executive of a Portuguese Medical cannabis company dedicated to the Production, Research & Development of Cannabis as a medicine.

Topics

Justin will be speaking on current & future landscapes of the medical cannabis industry. The challenges that companies & governments alike will face in creating protocols and standards in order to provide safe access for patients. He will also talk about public perception around medical cannabis and how that has changed over the years.

José Carlos Gonçalves_Photo.jpg

José Gonçalves - Lecturer

Short CV

José Carlos Gonçalves is Coordinator Professor at Escola Superior Agrária de Castelo Branco and Scientific Director of the Plant Biotechnology Center of Beira Interior. Graduated in Biology, Educational and Scientific branch, at the University of Coimbra and with a MSc in Plant Production and PhD in Agronomic Engineering from the Instituto Superior de Agronomia at the Lisbon University. He is a researcher of Center for Natural Resources, Environment and Society Studies (CERNAS), an FCT center and their research results are published in several journals, books and congress abstracts. Member of the editorial board of Biologia Plantarum journal and reviewer of several other journals. Develops research activity in the field of plant biotechnology, focusing on in vitro culture plant systems applied to plant propagation, germplasm preservation and secondary metabolites production.

Topics

In this talk we will address the general aspects of plant biotechnology, with reference to the different factors that allow the development of in vitro plant systems. The different areas of application of in vitro plant technologies will then be addressed, namely, germplasm conservation, plant multiplication, production of secondary metabolites and genetic engineering technologies.
This approach will be taken from a perspective of potential applications that could be the starting point for creating new products, processes or technologies and with them, new businesses.

José Pereira Leal_Photo.jpeg

José Pereira Leal 

Short CV

I am an entrepreneur, innovator, scientist, and manager. I founded an independent research group, a national research infrastructure, and a startup company in clinical genomics/ bioinformatics. I have 20+ years of a multidisciplinary international experience in multiple professional contexts to which I brought creativity, strategic thinking, and leadership. I am interested in the translation of scientific research into the solution of real life problems. My focus is on biotechnology, in particular genomics and bioinformatics, and their application for a better healthcare and a better, more sustainable use of natural resources.

Topics

Healthcare is undergoing a major transformation. This is partly due to the technological developments in areas such as genomics and AI, miniaturisation, among others. In addition, there is a shift from a model of medicine treating disease to the person being empowered to manage his/her own health and become the best version of him/herself, which concomitant rise of new health professions. Finally, new paradigms in service delivery, where we move to co-development models, service vs. ownership, etc., are also changing the healthcare landscape. This is a time of great change and as such, great opportunity. I'll discuss some recent technological developments mostly in genomics, AI and sensors and how they are leading to new business models.